The global osteoporosis drugs market accounted for $7,657 million in 2018 and is expected to reach $10,479 million by 2026, registering a CAGR of 3.9% from 2019 to 2026.
The major factor that contributes to the growth of the osteoporosis drugs market include a rise in The prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drugs market growth include a surge in the geriatric population across the globe and a rise in the adoption of a sedentary lifestyle worldwide. However, the side effects of osteoporosis drugs, and stringent regulatory environment and the time-consuming drug approval process hampers the growth of osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into bisphosphonates, selective oestrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. By route of administration, it is bifurcated into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global osteoporosis treatment market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Drug Class
- Bisphosphonates
- Selective Estrogen Inhibitors Modulator (SERM)
- Parathyroid Hormone Therapy
- Calcitonin
- Rank Ligand Inhibitors
- Others
By Route of administration
- Oral
- Injectable
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report:
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Radius Health, Inc.
- Merck & Co. Inc.
- Novartis International AG (Sandoz)
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
- GlaxoSmithKline plc
- Novo Nordisk A/S
Table of Contents
Executive Summary
According to this report titled, 'Osteoporosis Drugs Market by Drug Class, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global osteoporosis drugs market size was valued at $8 billion in 2018 and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.
Osteoporosis is a medical condition that involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on the quality of life of patients such as the condition that leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route.
The major factor that contributes toward the growth of the global osteoporosis drug market includes a rise in The prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drug market growth include a surge in the geriatric population across the globe and a rise in the adoption of a sedentary lifestyle worldwide. However, the side effects of osteoporosis drugs, and the time-consuming drug approval process restrain the growth of the global osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. By drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Depending on the route of administration, it is fragmented into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).
By drug class, the bisphosphonates segment acquired the major share of the osteoporosis drugs market in 2018 owing to an increase in investment in R&D of advanced novel bisphosphonates drugs by major players. However, rank ligand inhibitors segment is expected to exhibit the fastest growth rate during the forecast period owing to the fact that these drugs are used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway acts as an ideal treatment for bone metastasis which makes them a preferred choice of drug.
By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to a large number of osteoporosis medications that are available as oral drugs in the market. However, the injectable segment is expected to grow at the fastest CAGR during the forecast period owing to factors such as a rise in need for drugs that exhibit enhanced bioavailability, and act rapidly.
By region, North America accounted for the major osteoporosis drugs market share in 2018 and is expected to continue this trend, owing to the easy availability of osteoporosis drugs. Moreover, a surge in the incidence of osteoporosis is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia.
According to Onkar Sumant, Manager, Healthcare, “The demand for osteoporosis drugs is on a rise, owing to surge in the incidence of osteoporosis globally. Furthermore, a rise in healthcare expenditure leads to the easy availability of osteoporosis drugs, which fuels market growth.”
KEY FINDINGS OF THE STUDY
- Bisphosphonates occupied more than one-third share of the global osteoporosis drugs market in 2018.
- The RANK ligand inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
- The oral segment in drug class accounted for more than half the share of the market in 2018.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
Companies Mentioned
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Radius Health Inc. Merck & Co. Inc.
- Novartis International AG (Sandoz)
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
